CBS News reported that the Food and Drug Administration has announced that GLP-1 weight loss drugs will now include warning labels for a potential increased risk of vision loss. The account is a short video item, linked here as the CBS News video report on the FDA announcement.

According to CBS News, the labels indicate a "potential increased risk of vision loss." The report's summary does not identify the specific products that will carry the warning, and it does not describe the evidence the agency relied on in reaching its decision.

Because the source is a brief video summary, the available reporting does not state when the labeling change takes effect. It also does not say whether the warning applies to particular patients, doses, or treatment durations. The summary includes no reaction from drug manufacturers or medical groups.

The announcement is the only source reporting available for this account. No other outlet's coverage was reviewed for this story, so the facts reported here rest on a single source, and details beyond the core points of the announcement remain unconfirmed by this report.

Readers seeking the full terms of the labeling change should consult the Food and Drug Administration's own announcement, which was not part of the material reviewed for this story.

Sources: CBS News: GLP-1s must now include warning for potential increased risk of vision loss, FDA announces.